



Universiteit
Leiden
The Netherlands

Disentangling the relationship between depression, obesity and cardiometabolic disease

Alshehri, T.

Citation

Alshehri, T. (2023, November 30). *Disentangling the relationship between depression, obesity and cardiometabolic disease*. Retrieved from <https://hdl.handle.net/1887/3665477>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3665477>

Note: To cite this publication please use the final published version (if applicable).



4

Circulating metabolites modulated by diet are causally associated with depression

Ashley van der Spek[#], Isobel D. Stewart[#], Brigitte Kühnel[#], Maik Pietzner[#], Tahani Alshehri[#], Friederike Gauß, Pirro G. Hysi, Siamak Mahmoudian Dehkordi, Almut Heinken, Annemarie I. Luik, Karl-Heinz Ladwig, Gabi Kastenmüller, Cristina Menni, Johannes Hertel, M. Arfan Ikram, Renée de Mutsert, Karsten Suhre, Christian Gieger, Konstantin Strauch, Henry Völzke, Thomas Meitinger, Massimo Mangino, Antonia Flaquer, Melanie Waldenberger, Annette Peters, Ines Thiele, Rima Kaddurah-Daouk, Boadie W Dunlop, Frits R. Rosendaal, Nicholas J. Wareham, Tim D. Spector, Sonja Kunze[†], Hans Jürgen Grabe[†], Dennis O. Mook-Kanamori[†], Claudia Langenberg[†], Cornelia M. van Duijn[†], Najaf Amin[†]

[#] These authors contributed equally

[†] These authors contributed equally

ABSTRACT

Metabolome reflects the interplay of genome and exposome at molecular level and thus can provide deep insights into the pathogenesis of a complex disease like major depression. To identify metabolites associated with depression we performed a metabolome-wide association analysis in 13,596 participants from five European population-based cohorts characterized for depression, and circulating metabolites using ultra high-performance liquid chromatography/tandem accurate mass spectrometry (UHPLC/MS/MS) based Metabolon platform. We tested 806 metabolites covering a wide range of biochemical processes including those involved in lipid, amino-acid, energy, carbohydrate, xenobiotic and vitamin metabolism for their association with depression. In a conservative model adjusting for life style factors and cardiovascular and antidepressant medication use we identified 8 metabolites, including 6 novel, significantly associated with depression. In individuals with depression, increased levels of retinol (vitamin A), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) (lecithin) and mannitol/sorbitol and lower levels of hippurate, 4-hydroxycoumarin, 2-aminooctanoate (alpha-aminocaprylic acid), 10-undecenoate (11:1n1) (undecylenic acid), 1-linoleoyl-GPA (18:2) (lysophosphatidic acid; LPA 18:2) are observed. These metabolites are either directly food derived or are products of host and gut microbial metabolism of food-derived products. Hippurate and mannitol/sorbitol have previously been consistently associated with depression. Our Mendelian randomization analysis suggests that low hippurate levels are causally related to depression. Further analysis of dietary sources of the metabolites in the UK Biobank reveals that increased vitamin A intake may also have causal implications for major depression. Our findings highlight putative actionable targets for depression prevention that are easily modifiable through diet interventions.

INTRODUCTION

Depression is the most common psychiatric disorder with an average lifetime prevalence of 11-15% [1]. A sharp increase in the prevalence of depression worldwide (33.7%; confidence interval 27.5–40.6) has been observed during the recent COVID-19 pandemic [2] and is predicted to increase as the effects of the pandemic unfold further [3]. The molecular mechanisms underlying depression remain elusive. The heritability is estimated to be around 40% [4] and 87 genetic variants have been identified to be associated with depression [5]. There is also a range of environmental risk factors for morbidity including low education, diet and smoking [6]. There is increasing evidence that diet influences mood [7]. Depression also often co-occurs not-only with other neuro-psychiatric pathologies [8, 9], but also clusters strongly with systemic disorders such as cardiometabolic disease, diabetes and arthritis [10-13]. Treatment success for depression is poor and mortality is high [12, 14, 15]. While depression is primarily considered as a disorder of the brain [16], it is associated with metabolic changes in the blood circulation that may be explained by weight loss/gain, changes in diet and altered gut metabolism [17]. There is increasing interest in metabolomic studies of depression that capture the downstream effects of genes, lifestyle factors, pathology and medication [18-20]. A novel hypothesis why circulating metabolites may be involved in depression is that these metabolites are involved in the gut-brain axis, i.e., the bi-directional signalling between the gut, its microbiome and the brain [21, 22]. Metabolomic studies on depression have been small and findings have not always been consistent [23]. Yet, consensus is building that depression is associated with increased levels of glutamate, lactate, alanine, isobutyrate and sorbitol and with decreased levels of kynurenine, gamma aminobutyric acid (GABA), phenylalanine, tyrosine, creatinine, hypoxanthine, leucine, tryptophan, N-methylnicotinamide, β -aminoisobutyric acid, hippurate, amino-ethanol and malonate [24]. Our study of 5,283 patients with depression and 10,145 controls from nine Dutch cohorts [25] using a proton Nuclear Magnetic Resonance (NMR) metabolomics platform (Nightingale Health Ltd., Helsinki, Finland) identified 21 cardiometabolic metabolites that are significantly related to depression. These include an unfavorable spectrum of metabolites associated to cardiometabolic morbidity and mortality [26-28] including apolipoprotein A1 and B, very-low-density and high-density lipoprotein cholesterol, di- and triglycerides, (mono-) unsaturated fatty acids, fatty acid chain length, acetate, glycoprotein acetyls, tyrosine, and isoleucine [29].

A problem hampering the translation of findings of metabolomics studies into preventive and therapeutic interventions is that metabolites in the blood circulation are strongly influenced by medication and comorbidity [22]. Although their effects are well recognized, the potential bias is not controlled for in most

studies conducted to date. Another problem to be tackled is to disentangle metabolic changes that occur as a cause from those that occur because of depression progression. To control for confounding, we conducted a comprehensive analysis of the relation between the blood metabolome and depression in five large scale epidemiologic cohorts including a total of 13,596 participants. This setting allows us to control for confounding effects of medication and co-morbidity. The metabolome in the circulation was characterized by mass spectrometry (MS) using Metabolon. To identify the origin of metabolites (gut and/or human) we integrate our findings with those of the Virtual Metabolic Human (VMH) and Assembly of Gut Organisms through Reconstruction and Analysis (AGORA2) databases. To separate potential causal effects from the consequences of the disease, we integrate genomic and metabolomic data using the NIHR BioResource (NBR). We then examine the impact of anti-depressive therapy on the metabolites in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Finally, we study the association of the diet-based sources of these metabolites with depression and brain pathology in the UK Biobank.

METHODS

Study populations

The association analysis of metabolite levels with depression was performed in 13,596 participants separately recruited in five different cohort studies. The following cohort studies were included: the Rotterdam Study (RS), the Study of Health in Pomerania (SHIP-TREND), the Cooperative Health Research in the Region of Augsburg (KORA) study, the European Prospective Investigation into Cancer (EPIC)-Norfolk Study, and the Netherlands Epidemiology of Obesity (NEO) study. Detailed information on these cohorts is provided in the Supplementary Materials. All participants provided written informed consent, studies were approved by their local ethics committees and conformed to the principles of the declaration of Helsinki. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Association of depression with the dietary sources of the depression-associated metabolites was performed in the UK Biobank study. UK Biobank is a prospective cohort study including ~ 500,000 participants aged 40-69 years at baseline recruited between 2006 and 2010. The aim of the study is to investigate the effects of genetic and environmental factors on the risk of common multifactorial diseases. Participants have provided a detailed information on lifestyle, medical history and nutritional habits; basic variables such as weight, height, blood pressure etc. were measured; and blood and urine samples were taken. Detailed information about the cohort is provided in the Supplementary Materials.

To ascertain the effects of various depression treatments including cognitive behavioural therapy (CBT) and antidepressants SSRI (escitalopram) and SNRI (duloxetine) on the depression-associated metabolites we performed a lookup in the PRedICT study. The design of PRedICT study has been published previously. [28] Details on the study and the metabolomics assessments are provided in the Supplementary Materials.

To select instruments/proxies for metabolites for Mendelian Randomization we used the results of the genome-wide association study (GWAS) performed using the NIHR BioResource (NBR). NIHR BioResource (NBR) – Rare Disease Study is a multi-center whole-exome and whole-genome sequencing study including up to 13,600 patients (<http://bioresource.nihr.ac.uk/rare-diseases/rare-diseases/>). The NBR–Rare Diseases study was approved by the East of England Cambridge South national research ethics committee (REC) under reference number: 13/EE/0325. The inclusion and exclusion criteria, as well as other steps of quality control, adjustment and transformations followed the same analytical steps as described before [30].

Depression assessment

In the RS, depressive symptoms were assessed with the 20-item version of the Centre for Epidemiologic Studies Depression (CES-D) scale, a self-report measure of depressive symptoms experienced during the prior week [30]. The total score ranges from 0 – 60, where a higher score indicates more depressive symptoms. In the SHIP-trend and KORA cohorts, depressive symptoms were assessed with the Patient Health Questionnaire 9 (PHQ-9) [31], where each of the nine DSM-IV criteria for depression are scored from 0 – 3. The total score ranges from 0 – 27 where higher score indicates a greater depression severity. In KORA a brief interview version of PHQ-9 called Patient Health Questionnaire Depression (PHQ-D) module was used to measure depression [31, 32]. In the EPIC-Norfolk study depression was assessed using the following question: “Has the doctor ever told you that you have any of the following: depression requiring treatment?” with answers “yes” or “no”. In the NEO cohort, depressive symptoms were assessed using the Inventory Depressive Symptomatology Self Report questionnaire (IDS-SR30) [33], which assesses specific depressive symptoms (via a 4-level response system) during the last week and their severity. The total score ranges from 0 to 84, with higher scores indicating higher severity. Thus, in all cohorts except EPIC-Norfolk, depression in participants was measured on a quantitative scale and used as such in the analysis.

In the UKB study, we used the derived lifetime probable major depressive disorder measure as described in Smith et al. 2013 [34]. We further defined current depressive symptoms by summing the responses to four questions related to mood

in the past two weeks. These include, (1) Over the past two weeks, how often have you felt down, depressed or hopeless?, (2) Over the past two weeks, how often have you had little interest or pleasure in doing things?, (3) Over the past two weeks, how often have you felt tense, fidgety or restless? and (4) Over the past two weeks, how often have you felt tired or had little energy? Answers could be given on a four-point scale ranging from 0-3 (0 = not at all, 1 = several days, 2 = more than half of the days and 3 = nearly every day). The total score ranged from 0-12 where higher score indicating more severe depression.

In the PRedICT study, participants were treatment-naive adults defined as having never previously received a minimally adequate course of treatment with an antidepressant medication or evidence-based psychotherapy for a mood disorder, aged 18 to 65 years with moderate-to-severe, non-psychotic MDD depression as assessed by the Structured Clinical Interview for DSM-IV [35] and a psychiatrist's evaluation, and if they scored ≥ 18 on the HRSD17. Eligible patients were randomized equally to one of three 12-week treatment arms: (1) cognitive behavior therapy (CBT, 16 sessions); (2) duloxetine (30–60 mg/d); or (3) escitalopram (10–20 mg/d).

Metabolomics measurements

In all studies, the metabolome was quantified using the Metabolon platform (Metabolon Inc., Durham, USA). Different versions of the platform have been used and details on the platforms are included in the Supplementary Materials. In all studies, metabolites with $\geq 40\%$ missing values were removed and for the remaining metabolites missing metabolite values were replaced with half of the detection limit for that particular metabolite [36]. Subsequently, a natural logarithm transformation was applied to all metabolites and metabolites were scaled to standard deviation units.

In the PRedICT study, metabolites were quantified using targeted metabolomics platforms including ultra-performance liquid chromatography triple quadrupole mass spectrometry (UPLC-TQMS) (Waters XEVO TQ-S, Milford, USA) and gas chromatography time-of-flight mass spectrometry (GC-TOFMS) (Leco Corporation, St Joseph, USA). Metabolites with $>20\%$ missing values were excluded. Then, metabolites were log-transformed, imputed and scaled to mean zero and variance 1. Details are provided in the Supplementary Materials.

Non-targeted metabolite detection and quantification was conducted by the metabolomics provider Metabolon, Inc. (Durham, USA) on fasting plasma samples of 10,654 participants from the UK Bioresource. The metabolomic dataset measured by Metabolon included 1069 compounds of known structural identity belonging to the following broad categories - amino-acids, peptides, carbohydrates,

energy intermediates, lipids, nucleotides, cofactors and vitamins, and xenobiotics. Metabolites data were day-median normalized, and inverse normalized, as the metabolite concentrations were not normally distributed. Metabolic traits with more than 20% missing values were excluded leaving 722 metabolites of known chemical identity for analysis.

Genotyping

For the GWAS of metabolites, genotyping in the UK biobank was carried out with a high-density array data (Affymetrix UK Biobank Axiom® Array). Genotypes were subsequently imputed using information from the Human Reference Consortium imputation panel (version r1.1, 2016) [37]. Only individuals of full European ancestry (N=8,809) were included in the analyses in the discovery cohort.

Statistical analyses

Metabolites association analysis

All cohorts used linear regression analysis to test the association between the metabolite levels (dependent variable) and depression. Three different models were tested, where the first model (model 1) was adjusted for age and sex only, the second model (model 2) was additionally adjusted for antidepressant medication usage, and the third model was an extension of the second model (model 3) with additional adjustment for lipid-lowering medication (yes/no), antihypertensive medication (yes/no), antidiabetic medication (yes/no), BMI (kg/m²), and current smoking (yes/no). The summary statistics from all cohorts were combined in a sample size-weighted meta-analysis using METAL software [38]. Sample size weighted meta-analysis was used since the depression measurement scales were different among cohorts. Only metabolites that were present in two or more studies were included. To investigate the robustness of our findings, a sensitivity analysis was performed by including only cohorts that assessed metabolites with the most recent version of the Metabolon platform (HD4).

Association analysis of major depressive disorder with dietary sources of the metabolites in the UK Biobank

We used logistic regression analysis to test the association between major depressive disorder and dietary sources of metabolites (vitamin A supplements, retinol intake estimated from food, fresh fruits intake and vitamin K antagonists). Age, sex and principal components were used as covariates in the analysis. For the association of current depressive symptoms, we used linear regression analysis. We further tested the association of volume of white matter hyperintensities (WMH) with vitamin supplements to ascertain the impact of these supplements on brain pathology. Linear regression analysis was used with the volume of WMH

as the dependent variable, vitamin supplements as the independent variable, and age, sex, BMI, head size and principal components as covariates. All analyses were performed in R.

Metabolite GWAS for Mendelian Randomization (MR) analysis

To test for association between metabolite levels and genotypes, we built linear regression models where the outcome was defined as the transformed level of each metabolite, predicted by the allele dosage at each polymorphic (MAF > 0.01) genotyped or imputed genetic variant. In addition, analyses were adjusted for age, sex and BMI. All analyses were conducted using the PLINK software (<https://www.cog-genomics.org/plink/2.0/>).

Mendelian Randomization (MR) analysis

To understand the relationship between the identified metabolites and major depression we performed bidirectional two-sample MR analysis. For major depression we used the independent genome-wide significant single nucleotide polymorphisms (SNPs) reported by Howard et al. 2019 [5] as instrumental variables (IVs). Summary statistics for these IVs were extracted from Howard et al. The summary statistics for the metabolites were extracted from the GWAS performed in UK Biobank. Of the identified metabolites in this study (model 3), GWAS results were available for six metabolites including 2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1), hippurate, mannitol/sorbitol and retinol (Supplementary Table 1). The IVs for these six metabolites and their summary statistics were extracted from the same GWAS. Because of scarcity in GWAS-grade significance for SNPs associated with these metabolites, we used independent SNPs that showed the strongest association with a p-value < 10^{-06} as instruments (Supplementary Table 2). The summary statistics for depression for these IVs were extracted from the publicly available dataset (2019 PGC UKB Depression Genome-wide; <https://www.med.unc.edu/pgc/download-results/mdd/>). For the analysis we used the 'mr_allmethods' option of the R (<https://cran.r-project.org/>) library "MendelianRandomization" [39] that reports the results from the median method (simple, weighted and penalized), Inverse variance weighted and Egger methods (penalized, robust and penalized & robust).

Table 1. Descriptive statistics of the study populations.

	RS	SHIP-trend	KORA	EPIC-Norfolk B2	EPIC-Norfolk B3	NEO
N	484	965	1688	4639	5163	599
Ncases/Ncontrols	-	-	-	638/4001	685/4478	-
Mean age (years) (SD)	73.1 (6.3)	50.1 (13.6)	61 (8.8)	59.9 (8.8)	59.6 (8.9)	55.8 (6.0)
Age range (years)	62-96	20-81	32-77	40-78	40-78	45-66
Females (%)	52.5	56.0	51.4	52.4	52.8	52.6
Mean BMI (kg/m ²) (SD)	26.8 (3.7)	27.4 (4.6)	28.2 (4.8)	26.20 (3.7)	26.2 (3.8)	25.9 (4.0)
Smoking (%)	12.6	22.0	14.5	11.4	10.9	11.9
Medication						
Antidepressants (%)	3.7	4.0	5.6	4.5	3.8	5.3
Lipid-lowering medication (%)	10.5	7.8	16.7	1.4	1.5	7.7
Antihypertensives (%)	0.6	28.2	37.9	19.5	17.0	19.7
Antidiabetics (%)	5.4	0	7.5	1.9	2.0	2.7

88 **Table 2.** Top findings of the association analysis of metabolites with depression (FDR corrected *p-value* < 0.05 in model 1).

Chemical ID	Name	Model 1			Model 2			Model 3						
		Super pathway	N	Zscore	Direction*	FDR	N	Zscore	Direction*	FDR	N	Zscore	Direction*	FDR
100001197	10-undecenoate (11:1n1)	Lipid	13596	-5.12	+-----	8.02E-05	13556	-3.94	+-----	1.7E-02	13549	-3.79	+-----	2.71E-02
100001740	mannitol/sorbitol	Carbohydrate	12631	5.14	+?+??	8.02E-05	12592	3.39	+?+??	5.02E-02	12586	3.58	+?+??	4.47E-02
1090	bilirubin (Z,Z)	Cofactors and Vitamins	13596	-5.33	-----	8.02E-05	13556	-3.60	-----	3.5E-02	13549	-2.84	-----	1.83E-01
100001950	bilirubin (E,E)*	Cofactors and Vitamins	13596	-5.25	-----	8.02E-05	13556	-3.33	-----	5.13E-02	13549	-2.73	-----	2.08E-01
100002049	4-hydroxycoumarin	Xenobiotics	10885	-4.99	?-?--	1.30E-04	10847	-4.48	?-?--	4.0E-03	10847	-4.17	?-?--	1.12E-02
100008984	1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)*	Lipid	10885	4.84	+?+??	1.94E-04	10847	3.58	+?+??	3.5E-02	10847	3.51	+?+??	4.47E-02
100001951	bilirubin (E,Z or Z,E)*	Cofactors and Vitamins	12631	-4.74	?-?--	2.83E-04	12592	-3.50	?-?--	3.5E-02	12586	-2.98	?-?--	1.37E-01
498	retinol (Vitamin A)	Cofactors and Vitamins	10885	4.65	+?+??	3.58E-04	10847	3.89	+?+??	1.7E-02	10847	4.14	+?+??	1.12E-02
100004227	2-aminooctanoate	Lipid	11850	-4.65	-?-?--	3.58E-04	11811	-4.00	-?-?--	1.7E-02	11810	-3.92	-?-?--	1.87E-02
100002253	cinnamoylglycine	Xenobiotics	10885	-4.40	?-?--	9.38E-04	10847	-3.50	?-?--	3.5E-02	10847	-3.32	?-?--	6.71E-02
100000010	3-phenylpropionate (hydrocinnamate)	Xenobiotics	13596	-4.42	-----	9.38E-04	13556	-3.73	-----	2.9E-02	13549	-3.24	-----	7.89E-02
100001251	decanoylcarnitine (C10)	Lipid	13596	-4.35	+-----	1.02E-03	13556	-3.35	+-----	5.13E-02	13549	-3.15	+-----	8.53E-02
1526	1-palmitoyl-2-oleoyl-GPE (16:0/18:1)	Lipid	10885	4.36	+?+??	1.02E-03	10847	2.64	+?+??	2.12E-01	10847	2.44	+?+??	2.68E-01
250	biliverdin	Cofactors and Vitamins	13596	-4.29	-----	1.24E-03	13556	-2.88	-----	1.40E-01	13549	-2.41	-----	2.75E-01
504	serotonin	Amino acid	12631	-4.24	?-?--	1.49E-03	12592	0.18	?-?--	9.55E-01	12586	-0.02	?-?--	9.92E-01
192	N-acetylputrescine	Amino acid	10885	4.06	+?+??	3.01E-03	10847	2.09	+?+??	3.52E-01	10847	2.16	+?+??	3.44E-01
100002259	cis-4-decenoylcarnitine (C10:1)	Lipid	13596	-4.02	-----	3.27E-03	13556	-2.80	-----	1.58E-01	13549	-2.47	-----	2.68E-01

Table 2. Continued.

Chemical ID	Name	Model 1			Model 2			Model 3						
		Super pathway	N	Zscore	Direction*	FDR	N	Zscore	Direction*	FDR	N	Zscore	Direction*	FDR
212	5-methylthioadenosine (MTA)	Amino acid	10885	4.03	+??+++	3.27E-03	10847	2.09	+??+++	3.52E-01	10847	1.78	+??+++	4.91E-01
100000997	3-hydroxydecanoate	Lipid	11850	-3.97	+?----	3.89E-03	11811	-2.60	+?----	2.23E-01	11810	-2.39	+?----	2.75E-01
1539	1-palmitoyl-2-oleoyl-GPC (16:0/18:1)	Lipid	10885	3.85	+??+++	6.01E-03	10847	2.93	+??+++	1.36E-01	10847	2.76	+??+++	2.03E-01
100000014	hippurate	Xenobiotics	13596	-3.80	-----	7.10E-03	13556	-4.17	-----	1.1E-02	13549	-3.72	-----	2.99E-02
100001392	laurylcarnitine (C12)	Lipid	13596	-3.73	+-----	8.97E-03	13556	-2.68	+-----	1.96E-01	13549	-2.61	+-----	2.48E-01
1128	2-aminobutyrate	Amino acid	13596	-3.68	-----	9.61E-03	13556	-2.08	---+---	3.54E-01	13549	-1.84	---+---	4.74E-01
561	glutamate	Amino acid	13596	3.70	++++++	9.61E-03	13556	1.92	++++++	4.13E-01	13549	1.15	++++++	7.26E-01
98	kynurenate	Amino acid	10885	-3.61	?-?---	1.22E-02	10847	-2.79	?-?---	1.58E-01	10847	-2.50	?-?---	2.68E-01
100001658	taurothiocholate 3-sulfate	Lipid	13596	-3.52	-----	1.45E-02	13556	-3.09	-----	9.31E-02	13549	-3.09	-----	1.01E-01
100001511	1-palmitoleyl-GPC (16:1)*	Lipid	13596	3.54	+++++	1.45E-02	13556	2.43	+++++	2.74E-01	13549	2.57	+++++	2.48E-01
100001112	3-hydroxylaurate	Lipid	10885	-3.53	?-?---	1.45E-02	10847	-2.54	?-?---	2.42E-01	10847	-2.43	?-?---	2.69E-01
100008990	1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)*	Lipid	10885	3.52	?-?+++	1.45E-02	10847	2.22	?-?+++	3.00E-01	10847	2.23	?-?+++	3.27E-01
100000773	3-hydroxyoctanoate	Lipid	11850	-3.54	+?----	1.45E-02	11811	-2.25	+?----	3.00E-01	11810	-2.13	+?----	3.63E-01
100001868	4-allylphenol sulfate	Xenobiotics	10885	-3.48	?-?---	1.58E-02	10847	-2.86	?-?---	1.46E-01	10847	-2.46	?-?---	2.68E-01
100001247	octanoylcarnitine (C8)	Lipid	13596	-3.47	+-----	1.58E-02	13556	-2.62	+-----	2.14E-01	13549	-2.48	+-----	2.68E-01
100001083	indolepropionate	Amino acid	13596	-3.48	-----	1.58E-02	13556	-2.95	-----	1.35E-01	13549	-2.12	-----	3.66E-01
100001977	beta-cryptoxanthin	Xenobiotics	6246	-3.46	?-?---	1.60E-02	6208	-3.25	?-?---	5.74E-02	6208	-2.59	?-?---	2.48E-01
100006430	arabitol/xylitol	Carbohydrate	12631	3.44	?+?+++	1.65E-02	12592	2.48	?+?+++	2.51E-01	12586	2.69	?+?+++	2.15E-01
100009082	1-linoleyl-GPA (18:2)*	Lipid	10885	-3.39	?-?---	1.91E-02	10847	-3.57	?-?---	3.5E-02	10847	-3.53	?-?---	4.47E-02
100001870	1-palmitoyl-2-linoleoyl-GPE (16:0/18:2)	Lipid	10885	3.39	?-?+++	1.91E-02	10847	2.02	?-?+++	3.78E-01	10847	2.18	?-?+++	3.41E-01

Table 2. Continued.

Chemical ID	Name	Model 1				Model 2				Model 3				
		Super pathway	N	Zscore	Direction*	FDR	N	Zscore	Direction*	FDR	N	Zscore	Direction*	FDR
100000257	glucuronate	Carbohydrate	10885	3.35	+?+??	2.18E-02	10847	2.09	+?+??	3.52E-01	10847	1.93	+?+??	4.51E-01
391	citruiline	Amino acid	13596	-3.31	-----	2.45E-02	13556	-3.53	-----	3.5E-02	13549	-3.29	-----	7.22E-02
100001121	pyridoxate	Cofactors and Vitamins	13596	3.29	+++??	2.50E-02	13556	2.71	+++??	1.83E-01	13549	3.17	+++??	8.53E-02
100002021	5alpha-androstan-3beta,17alpha-diol disulfate	Lipid	10885	-3.25	-?+??	2.79E-02	10847	-2.05	-?+??	3.67E-01	10847	-1.63	-?+??	5.35E-01
100001287	epiandrosterone sulfate	Lipid	13596	-3.16	+-----	3.59E-02	13556	-1.71	+-----	4.70E-01	13549	-1.73	+-----	5.03E-01
100008914	1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6)	Lipid	10885	3.13	-?+??	3.89E-02	10847	2.92	-?+??	1.36E-01	10847	2.94	-?+??	1.52E-01
100001320	erythronate*	Carbohydrate	12631	3.12	+?+??	3.89E-02	12592	1.76	+?+??	4.55E-01	12586	1.77	+?+??	4.91E-01
935	sucrose	Carbohydrate	10885	3.13	+?+??	3.89E-02	10847	1.61	+?+??	4.99E-01	10847	1.16	+?+??	7.21E-01
100001567	1-palmitoyl-GPE (16:0)	Lipid	13596	3.10	+++??	4.01E-02	13556	2.15	+++??	3.28E-01	13549	2.57	++++??	2.48E-01
100008991	1-palmitoyl-2-docosahexaenoyl-GPE (16.0/22.6)	Lipid	10401	3.06	??+??	4.26E-02	10401	2.43	??+??	2.74E-01	10401	2.71	??+??	2.15E-01
100001657	glycolithocholate sulfate*	Lipid	11850	-3.06	-?-?+	4.26E-02	11811	-2.46	-?-?+	2.60E-01	11810	-2.29	-?-?+	3.09E-01
100008977	1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)	Lipid	10885	3.07	-?+??	4.26E-02	10847	1.94	-?+??	4.07E-01	10847	1.93	-?+??	4.51E-01
823	pyruvate	Carbohydrate	13596	3.06	++++??	4.26E-02	13556	2.28	++++??	2.91E-01	13549	1.84	+----?	4.74E-01
397	leucine	Amino acid	13596	-3.04	-+----?	4.44E-02	13556	-2.73	-+----?	1.76E-01	13549	-3.33	-----	6.71E-02
100002945	15-methylpalmitate	Lipid	13596	-3.04	+-----	4.44E-02	13556	-2.77	+-----	1.63E-01	13549	-2.40	+-----	2.75E-01
100009066	1-palmitoyl-2-oleoyl-GPI (16:0/18:1)*	Lipid	6246	3.03	+??+??	4.50E-02	6208	1.96	+??+??	4.01E-01	6208	1.86	+??+??	4.66E-01

* The order of the direction column: RS, SHIP-trend, KORa, EPIC-Norfolk B2, EPIC-Norfolk B3, NEO

Effect of antidepressant therapy on metabolites in PReDICT study

To examine the strength and significance of metabolite concentration changes within each of the three treatment arms, i.e., (1) CBT (16 sessions); (2) duloxetine (30–60 mg/d); or (3) escitalopram (10–20 mg/d), linear mixed effect models (with random intercept) with metabolite levels (in log scale) as the dependent variable, were fitted while correcting for age, sex, BMI, and baseline HRSD17. Then, the R package “emmeans” was used to compute the least squared means of the contrasts of interest (week 12 vs. baseline) and their corresponding p-values.

To detect whether metabolites levels were associated with clinical outcomes, linear regression analyses corrected for age, sex and treatment arm were performed. Dependent variables (Baseline HRSD17, Week 12 HRSD17, and 12 weeks change in HRSD17) were regressed on either of following independent variables: 1) baseline metabolite, 2) week 12 metabolite, 3) 2 weeks change in metabolites and 4) 12 weeks change in metabolites.

Linking metabolites to human and/or gut metabolism

To assess whether the identified metabolites are products of human metabolism, gut microbial metabolism, or both, we integrated our findings with those of the Virtual Metabolic Human (VMH) and Assembly of Gut Organisms through Reconstruction and Analysis (AGORA2) databases. Additional information is provided in the Supplementary Materials.

RESULTS

This study includes 13,596 participants from five independent cohorts including the Rotterdam Study (RS), the Study of Health in Pomerania (SHIP-TREND), the Cooperative Health Research in the Region of Augsburg (KORA) study, the European Prospective Investigation into Cancer (EPIC)-Norfolk Study, and the Netherlands Epidemiology of Obesity (NEO) study. A detailed description of the study participants is provided in Table 1. Depression was measured on a quantitative scale in all cohorts except the EPIC-Norfolk study, where the participants reported depression on a yes/no scale. The mean age ranged from 50.1 years in SHIP-Trend to 73.1 years in the Rotterdam Study. The percentage of female participants (51-56%) and mean body mass index (BMI; between 26-28 kg/m²) were comparable between studies. There were differences in the percentage of smokers between the cohorts, ranging from 11% in EPIC-Norfolk and to 22% in SHIP-Trend.

When testing for an association with depression adjusting for age and sex, 53 (41 novel) metabolites were significantly associated with depression after adjusting for multiple testing (false discovery rate (FDR) < 0.05; Table 2 & Figure 1). These

include nine metabolites in the amino acid metabolism pathway including five previously associated with depression (leucine, kynurenate, citrulline, glutamate and serotonin) [23, 40, 41] and four novel metabolites (N-acetylputrescine, 5-methylthioadenosine (MTA), 2-aminobutyrate and indolepropionate). In addition, significant association was found for six carbohydrates (one novel), six cofactors and vitamins, all of which were novel, 26 lipids (25 novel), and six xenobiotics (five novel) (Table 2).




Figure 1. Association plot of metabolites with depression. This plot shows the top findings of the association analysis of metabolites with depressive symptoms, for all three models tested. Only metabolites with FDR p-value < 0.1 are shown in this Figure. The associations with a negative Z-score are depicted in grey, while the positive associations are depicted in orange. The plot is divided per metabolite subgroup. Significance levels: **: FDR < 0.001, *: FDR < 0.05. Script for Figure modified from Nath et al. (Genome Biol, 2017. 18(1): p. 146.).

When adjusting for antidepressant use (model 2), 12 metabolites remained significantly associated (FDR < 0.05) with depression (Table 2, Figure 1), suggesting that most associations observed with depression were confounded by antidepressant medication use. Of the amino acids, only citrulline remained

significantly associated with depression after adjustment for antidepressant medication (Table 2, Figure 1). Other metabolites that remained significantly associated with depression in the extended model included four xenobiotics (4-hydroxycoumarin, hippurate, 3-phenylpropionate (hydrocinnamate) and cinnamoylglycine), four lipids (2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and 1-linoleoyl-GPA (18:2)), and three cofactors and vitamins (retinol (vitamin A), bilirubin (Z,Z), bilirubin (E,Z or Z,E)). Among these, higher levels of 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and retinol (vitamin A) were associated with an increased risk of depression, while the others were associated with a decreased risk (Figure 1).

We subsequently build a more conservative model, further adjusting for other medication use, including lipid-lowering medication, antihypertensive medication, antidiabetic medication, BMI and current smoking (model 3). Seven out of the 12 metabolites remained significantly associated with depression (Table 2). These included retinol (vitamin A), hippurate, 4-hydroxycoumarin, 2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1), and 1-linoleoyl-GPA (18:2). Additionally, mannitol/sorbitol appeared statistically significant in model 3. Complete results of the meta-analysis are available in Supplementary Table 3.

There was no significant evidence for effect modification by sex (Supplementary Table 4) and the directionality of effects tended to be consistent in men and women. Effect sizes appeared to be stronger in women. Results were consistent across various versions of the Metabolon platform and depression assessing instruments and a sensitivity meta-analysis, which only included results from cohorts that had assessed metabolites on the most recent (HD4) platform, showed that they remained essentially unchanged (Supplementary Table 5).

Association of depression with dietary sources of metabolites in the UK Biobank

To evaluate the association of food sources of the identified metabolites with major depression we conducted a series of analyses in the UK Biobank (UKB). In the UKB information on vitamin supplements including vitamin A, retinol intake from food, consumption of fresh fruits – a major source of hippurate, and medication use including vitamin k antagonist (a proxy for 4-hydroxycoumarin) was available. In a cross-sectional analysis, we found a significant positive association of vitamin A intake from supplements with both measures of depression including current depressive symptoms ($\beta = 0.23$, $p\text{-value} = 1.25 \times 10^{-25}$) and lifetime major depressive disorder (MDD, OR = 1.40, $p\text{-value} = 9.72 \times 10^{-18}$). However, vitamin D supplement intake was also significantly positively associated with both measures of depression (Table 3), suggesting that depressed individuals take more vitamin supplements than non-depressed individuals.

Table 3. Results of association of depression outcomes with dietary sources of metabolites in the UK Biobank.

	Current depressive symptoms			Major Depressive Disorder (MDD)							
	N	Beta	SE	p-value	N	Beta	SE	p-value	OR	Lower 95% CI	Upper 95% CI
Vitamin A supplements	304399	0.23	0.02	1.25E-25	189800	0.34	0.04	9.72E-18	1.40	1.30	1.52
Vitamin D supplement	313100	0.19	0.02	5.07E-32	194681	0.34	0.03	1.22E-34	1.41	1.33	1.48
Retinol intake from food	61363	2.29E-04	4.02E-05	1.26E-08	38758	1.76E-04	5.50E-05	1.37E-03	1.00	1.00	1.00
Fresh fruits intake	434770	-0.06	0.002	1.61E-205	264796	-0.04	0.004	3.27E-22	0.96	0.96	0.97
Vitamin K antagonists use	435867	0.43	0.03	1.04E-46	265648	0.14	0.06	0.016	1.15	1.03	1.28

Since both vitamin A and vitamin D are fat-soluble and can cross the blood-brain barrier, we performed additional association with the measure of brain pathology, i.e., white matter hyperintensity (WMH) volume. Only vitamin A supplement intake was found to be associated with higher volume of WMH (beta = 479.09, p-value = 0.04, Supplementary Table 6), suggesting a possible role of vitamin A in brain diseases. To address the issue of reverse causality, we additionally tested the association of depression with retinol intake estimated from the food consumed in the previous 24 hours. Significant positive association of estimated retinol intake was observed with both measures of depression (current depressive symptoms, p-value = 1.26×10^{-08} ; lifetime MDD, p-value = 1.4×10^{-03}). However, the effect estimates were small (Table 3), which may in part be explained by the imprecision of food consumption questionnaires. Fresh fruit intake, a major source of hippurate, was negatively associated with both measures of depression (current depressive symptoms, beta = -0.06, p-value = 1.61×10^{-205} ; lifetime MDD, OR = 0.96, p-value = 3.27×10^{-22}) and vitamin K antagonists, a proxy for 4-hydroxycoumarin, was positively associated with both measures of depression (current depressive symptoms, beta = 0.43, p-value = 1.04×10^{-46} ; lifetime MDD, OR = 1.15, p-value = 0.016) (Table 3).

Mendelian randomization analysis

Testing the hypothesis that major depression results in changes of circulating metabolites in the Mendelian randomization analysis (MR), nominally significant results were obtained for 2-aminooctanoate and 10-undecenoate (11:1n1), under the MR-Egger method and weighted median method, respectively. However, these findings did not remain significant after adjustment for multiple testing (Supplementary Table 7). MR models in which we tested the hypothesis that levels of circulating metabolites increase the risk of depression provided significant evidence for a causal relation between hippurate and the risk of depression, both in the MR-Egger robust and penalized-robust methods (Supplementary Table 8). The effect estimate was consistent with the inverse relationship observed between hippurate and major depression in this study. However, a significant intercept was also observed suggesting pleiotropy. To exclude a pleiotropic effect, we studied the effect of intervention on the metabolite in the PRoDICT trial.

Effect of antidepressant therapy on hippurate

To further evaluate the impact of antidepressant therapy including cognitive behavioral therapy (CBT), duloxetine – a serotonin-norepinephrine reuptake inhibitor (SNRI) and escitalopram – a selective serotonin reuptake inhibitor (SSRI) on hippurate we consulted the PRoDICT study. The PRoDICT study allows us to test the effect of antidepressant therapy on the metabolite levels in circulation by measuring the metabolite levels before and after the antidepressant therapy. In PRoDICT, we found that levels of hippurate in the circulation increased significantly

from baseline to week 12 only after treatment with escitalopram (estimated week 12 vs. baseline difference = 0.45, 95% confidence interval (CI; 0.16,0.74), p-value = 0.002; Supplementary Figure 1), but not in the cognitive behaviour therapy (CBT) and duloxetine treatment arms (CBT: estimated difference = -0.02, 95% CI (-0.39,0.33) and p-value = 0.87; duloxetine: estimated difference = 0.13, 95% CI (-0.17,0.44) and p-value = 0.38). In this study, we could not show a relation between hippurate and depression as the study recruited patients only and lacked healthy controls. In patients receiving pharmacotherapy (escitalopram and duloxetine arms), the association of baseline depression as measured by the 17-item Hamilton Rating Scale for Depression (HRSD17) and baseline hippurate was not statistically significant (beta = 0.04, 95% CI (-0.03,0.11), p-value = 0.27). Further, no significant association was observed between depression in week 12 as measured by the HRSD17 and week 12 hippurate (beta = 0.09, p-value = 0.45) and 12 weeks change in HRSD17 and 12 weeks change in hippurate (beta = 0.02, 95% CI (-0.65, 1.57), p-value = 0.85).

Linking the human circulating metabolome to gut microbiome metabolism

Of the 53 metabolites identified in this study in model 1, 28 metabolites could be matched to a unique VMH metabolite ID. For each metabolite, the presence or absence in the global human reconstruction, Recon3D [42], and a resource of 7,206 reconstructions of human gut microbes, AGORA2 (<https://www.biorxiv.org/content/10.1101/2020.11.09.375451v1>) was retrieved. In total, 12 metabolites were present in both the human and gut microbial metabolic networks, three were only present in gut microbes, and 13 were only present in human (Supplementary Table 9). To further investigate potential links between the microbiome and metabolites associated with depression, the potential of the 7,206 AGORA2 strains to consume or secrete the 15 microbial metabolites identified in this study was computed. Since hippurate is synthesized in the liver and renal cortex from the microbial metabolite benzoate [43], the uptake and secretion potential for benzoate was also predicted for the 7,206 strains.

A wide range of genera and species were involved in the uptake of mannitol (Supplementary Table 10). Mannitol is largely secreted by several species of the genus *Bacteroides* followed by *Lactobacillus*, among others (Supplementary Table 11). Both genera have previously been found to be associated with depression [17]. In total, 3,616 AGORA2 strains mainly of the Gammaproteobacteria and Bacilli classes (Supplementary Table 11) synthesized benzoate as a product of benzamide (VMH reaction ID: BZAMAH). Interestingly, benzamides are a class of antipsychotic medication.

DISCUSSION

In this study, we identified 53 metabolites significantly associated with depression, most of which, including those in the monoamine and neurotransmitter pathways (serotonin, kynurenate and glutamate), were explained by antidepressant use. We identified novel associations with depression for six metabolites, including retinol (vitamin A), 4-hydroxycoumarin, 2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1), 1-linoleoyl-GPA (18:2) and confirmed the association of hippurate and mannitol/sorbitol. We found that the relation of hippurate and depression may be causal and that hippurate levels can be modified by a specific antidepressant, escitalopram. Analysing the major dietary sources of these metabolites in the UKB study, we found that retinol (vitamin A) intake was significantly higher and fresh fruits intake, a major source of hippurate, significantly lower in depressed individuals compared to those who were not depressed.

One of the most interesting findings of this study is the identification of the association of higher levels of retinol (active form of vitamin A) with depression. There have been several case reports of individuals with vitamin A intoxication with no previous history of depression, who developed symptoms of depression and even psychosis when overdosed with vitamin A [44, 45]. Depressive symptoms resolved upon discontinuation of vitamin A, implying that depression may be a side effect of vitamin A intake [44]. Animal models have suggested elevated monoamine oxidase enzyme activity and depression-related behavior upon vitamin A supplementation [46, 47]. Our study is the first to link higher levels of retinol in blood with depression in the general population. Retinol and its derivatives known as retinoids are lipid soluble and can cross the blood-brain barrier. Vitamin A is required for brain development and functioning [48, 49]. However, excess of vitamin A is neurotoxic and may result in brain shrinkage [49]. Brain areas high in retinoic acid signaling and receptors overlap with areas of relevance to stress and depression [50]. Further, vitamin A is known to increase the synthesis of triglyceride-rich very low-density lipoproteins (VLDLs) and apolipoproteins in the serum [51, 52], which we found associated with depression in our previous study [53]. Since food is the primary source of vitamin A, an important question to answer is whether vitamin A intake is associated to depression. In the UK Biobank we found significant increase in dietary retinol intake in individuals with depression. Thus, our findings ask for intervention studies that evaluate prospectively the effect of vitamin A reduction in depressed patients.

Two of the most strongly associated metabolites with depression were xenobiotics, hippurate and 4-hydroxycoumarin. In line with the findings of our study, decreased levels of hippurate have been previously reported in urine and plasma

of individuals with unipolar and bipolar depression consistently in several studies and it has been suggested as a biomarker for depressive disorders [54]. Our MR analysis suggests that low hippurate levels in circulation are a part of the causal pathway leading to depression. However, as the MR could not exclude a pleiotropic effect, our findings yield a hypothesis that requires further evaluation in a clinical trial. While we could not show an association between hippurate and depression in the PRedICT study, as the study lacked controls, hippurate levels were higher 12 weeks after initiation of selective serotonin reuptake inhibitor (SSRI) therapy (escitalopram) but not for SNRI or CBT, raising the question whether blood levels of hippurate can be used in clinical trials for compliance and efficiency of SSRIs specifically. Hippurate is derived from benzoate and polyphenols and is reported to be a metabolomics marker of gut microbiome diversity [53]. A diet rich in whole grains and fruits has been reported to increase levels of Hippurate [53]. In line with the decreased levels of hippurate in depressed individuals found in our metabolome-wide association analysis, we found significantly decreased fresh fruit intake among individuals with depression in the UKB, which is in line with the previous study that high consumption of fruits, vegetables, nuts, and legumes is associated with a reduced risk of depression [7, 55].

The metabolite 4-hydroxycoumarin is a fungal derivative of coumarin. Coumarins are found naturally in plants and spices [55] and coumarin is converted into 4-hydroxycoumarin by fungi [56]. 4-hydroxycoumarin is then converted into dicoumarol in the presence of formaldehyde [56]. Dicoumarol is an anticoagulant (warfarin) that inhibits the synthesis of vitamin K, also called vitamin K antagonist, and is commonly used to treat thromboembolic diseases [57]. In the UKB, we found significant positive association of anticoagulant use (vitamin K antagonists) with major depression. A history of depression is a risk factor for thromboembolism [58-60]. Antidepressants are also known to interact with warfarin [61] and are also associated with increased risk of thromboembolism [62]. Taking all findings together, we hypothesize that depression/antidepressant use depletes 4-hydroxycoumarin in circulation leading to thromboembolism. Vitamin K has been shown to act in the nervous system as it is involved in sphingolipid synthesis [63]. Sphingolipids are present in high concentrations in cell membranes of neuronal and glial cells [64]. Sphingolipids are essential for important cellular events, including proliferation, differentiation, senescence, cell-cell interactions, and transformation [65] and they have been linked to aging, Alzheimer's disease, and Parkinson's disease [66-68]. Further, sphingolipids were found to play a crucial role in the development of depression- and anxiety-related behaviours in mice [69, 70] and depression is seen often in patients with sphingolipid storage diseases [71-75]. Treatment with escitalopram /citalopram is also associated with changes in sphingolipids [76]. In our study, we did not find an association of depression with circulating sphingolipids present on the Metabolon platform. However, we cannot

exclude that 4-hydroxycoumarin in the blood affects sphingolipid metabolism in the brain specifically.

Other metabolites that were found to be significant in our study include mannitol/sorbitol, of which increased levels were associated with depression. Higher levels of sorbitol in plasma and urine have previously been consistently reported in patients with unipolar and bipolar depression and, like hippurate, it has been suggested as a diagnostic biomarker of depression [23]. Mannitol/sorbitol are sugar alcohols found in food such as fruits and berries and often used in diet/sugar free foods as sweeteners [77]. Fructose reduced diets have been shown to improve gastrointestinal disorders, depression and mood disorders [78]. Our AGORA2 analysis suggests that mannitol is mainly secreted by several species of *Bacteroides*, *Lactobacillus*, *Fructobacillus*, *Alistipes* and *Bifidobacterium*. Interestingly, all genera, except for *Fructobacillus* have previously been associated with depression [17], asking for further studies on the role of the microbiome, circulating levels of mannitol and depression.

Finally, there were four lipids identified in our study (2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and 1-linoleoyl-GPA (18:2)) significantly associated with depression. 1-Palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) also known as phosphatidylcholine (16:0/16:1) or lecithin (HMDB0007969) is commonly found in foods like eggs, soybean, liver, nuts and seeds and is a precursor of choline. Lecithin is believed to cause depression by increasing the production of acetylcholine in the brain [79]. When fed to animals and humans, lecithin significantly increases the levels of choline in blood and brain and of acetylcholine in brain [80-82]. Our study is the first to show higher circulating levels of lecithin in the depressed individuals from the general population. The other three lipids 2-aminooctanoate, 10-undecenoate (11:1n1) and 1-linoleoyl-GPA (18:2) were negatively associated with depression. 2-Aminooctanoate (alpha-aminocaproic acid) and 10-undecenoate (11:1n1) (undecylenic acid) are neutral hydrophobic molecules for which there is not much known in the literature. Lower levels of 10-undecenoate (11:1n1) have been found in individuals with non-alcoholic fatty liver disease [83]. 1-linoleoyl-GPA (18:2) is a lysophosphatidic acid (LPA 18:2). LPA is a bioactive membrane lipid that acts on at least six distinct G protein-coupled receptors (LPA1-6) and plays a role in pain sensitivity and emotional regulation [84]. LPA knock out mice exhibit anxiety-related behaviour [84, 85].

We found that decreased plasma levels of serotonin, kynurenate, leucine and citrulline and higher levels of glutamate were associated with depression. Lower plasma/serum levels of serotonin, kynurenate, citrulline and leucine and higher levels of glutamate have been reported in relationship to depression in earlier

studies [40, 41, 86, 87], which also appears consistent with our findings of model 1. However, we and others have shown that antidepressants affect plasma/serum levels of serotonin, glutamate, leucine and kynurenine [87-91]. An important finding of our study is that only citrulline remained significantly associated with depression after adjusting for antidepressant medication use. Lower levels of citrulline and its precursor arginine were previously associated to depression in unmedicated individuals [41, 92]. Interestingly, treatment with SSRIs significantly increase the levels of plasma citrulline [93]. Further, levels of plasma citrulline were found to be significantly increased two hours post treatment with ketamine, suggesting a possible mechanism of action of the rapid acting drug [92]. Citrulline is an intermediate in the urea cycle and linked to nitric-oxide synthesis [93]. It is absorbed by the gut and has useful therapeutic effects against cardiovascular diseases [94]. In our study the association of citrulline with depression lost its significance, albeit not completely, after adjusting for cardiovascular medication use and BMI.

Our study is the first large-scale effort combining metabolites measured on assorted, untargeted metabolomics platforms (Metabolon) studied in relationship to depression. In addition to confirming several previously identified metabolites in smaller studies, we successfully identified novel metabolites that are associated with depression. Our findings are robust across different versions of the Metabolon platform or the criteria assessing presence of clinical or subclinical depression. A possible limitation of our study is that differences in metabolomics platforms and technologies that were used by different cohorts to assess depression may have resulted in a reduction of statistical power. Older versions of the Metabolon platform reported significantly fewer known metabolites compared to the more recent implementations. Another possible limitation of our study is the presence of residual confounding. After adjusting for medication use and the lifestyle factors smoking and BMI, confounding may still be present and may influence the results [95]. Also, our MR analysis was most likely underpowered lacking strong instrumental variables for both depression and the associated metabolites.

Analysing circulating levels of 806 metabolites from untargeted metabolomics platforms in 13,596 individuals, we identified six new associations of metabolites with depression including retinol (vitamin A), 4-hydroxycoumarin and four lipids, 2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and 1-linoleoyl-GPA (18:2), while confirming known associations of hippurate and mannitol/sorbitol. We further show that previously identified associations of depression with metabolites belonging to the amino-acid pathways including serotonin, kynurenate, leucine and glutamate are likely explained by antidepressant medication. Our findings point to effective preventive targets, as most of these metabolites are food derived and thus can be altered in patients by modifying diet.

REFERENCES

1. Bromet, E., et al., *Cross-national epidemiology of DSM-IV major depressive episode*. BMC Med, 2011. **9**: p. 90.
2. Salari, N., et al., *Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis*. Global Health, 2020. **16**(1): p. 57.
3. Sher, L., *The impact of the COVID-19 pandemic on suicide rates*. Qjm, 2020. **113**(10): p. 707-712.
4. Sullivan, P.F., M.C. Neale, and K.S. Kendler, *Genetic epidemiology of major depression: review and meta-analysis*. Am J Psychiatry, 2000. **157**(10): p. 1552-62.
5. Howard, D.M., et al., *Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions*. Nat Neurosci, 2019. **22**(3): p. 343-352.
6. Batterham, P.J., H. Christensen, and A.J. Mackinnon, *Modifiable risk factors predicting major depressive disorder at four year follow-up: a decision tree approach*. BMC Psychiatry, 2009. **9**: p. 75.
7. Firth, J., et al., *Food and mood: how do diet and nutrition affect mental wellbeing?* Bmj, 2020. **369**: p. m2382.
8. Beekman, A.T., et al., *Anxiety and depression in later life: Co-occurrence and communality of risk factors*. Am J Psychiatry, 2000. **157**(1): p. 89-95.
9. Moffitt, T.E., et al., *Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years*. Arch Gen Psychiatry, 2007. **64**(6): p. 651-60.
10. Kang, H.J., et al., *Comorbidity of depression with physical disorders: research and clinical implications*. Chonnam Med J, 2015. **51**(1): p. 8-18.
11. Judd, L.L., *The clinical course of unipolar major depressive disorders*. Arch Gen Psychiatry, 1997. **54**(11): p. 989-91.
12. Lopez, A.D., et al., *Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data*. Lancet, 2006. **367**(9524): p. 1747-57.
13. Wittchen, H.U., et al., *The size and burden of mental disorders and other disorders of the brain in Europe 2010*. Eur Neuropsychopharmacol, 2011. **21**(9): p. 655-79.
14. Angst, F., et al., *Mortality of patients with mood disorders: follow-up over 34-38 years*. J Affect Disord, 2002. **68**(2-3): p. 167-81.
15. Korte, S.M., et al., *The many different faces of major depression: it is time for personalized medicine*. Eur J Pharmacol, 2015. **753**: p. 88-104.
16. Pandya, M., et al., *Where in the brain is depression?* Curr Psychiatry Rep, 2012. **14**(6): p. 634-42.
17. Cheung, S.G., et al., *Systematic Review of Gut Microbiota and Major Depression*. Front Psychiatry, 2019. **10**: p. 34.

18. Sethi, S. and E. Brietzke, *Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders*. Int J Neuropsychopharmacol, 2015. **19**(3): p. pyv096.
19. Quinones, M.P. and R. Kaddurah-Daouk, *Metabolomics tools for identifying biomarkers for neuropsychiatric diseases*. Neurobiol Dis, 2009. **35**(2): p. 165-76.
20. Patti, G.J., O. Yanes, and G. Siuzdak, *Innovation: Metabolomics: the apogee of the omics trilogy*. Nat Rev Mol Cell Biol, 2012. **13**(4): p. 263-9.
21. Valles-Colomer, M., et al., *The neuroactive potential of the human gut microbiota in quality of life and depression*. Nat Microbiol, 2019. **4**(4): p. 623-632.
22. Liu, J., et al., *Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas*. Nat Med, 2020. **26**(1): p. 110-117.
23. MacDonald, K., et al., *Biomarkers for major depressive and bipolar disorders using metabolomics: A systematic review*. Am J Med Genet B Neuropsychiatr Genet, 2019. **180**(2): p. 122-137.
24. Bot, M., et al., *Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls*. Biol Psychiatry, 2020. **87**(5): p. 409-418.
25. Deelen, J., et al., *A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals*. Nat Commun, 2019. **10**(1): p. 3346.
26. Würtz, P., et al., *Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts*. Circulation, 2015. **131**(9): p. 774-85.
27. Ahola-Olli, A.V., et al., *Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts*. Diabetologia, 2019. **62**(12): p. 2298-2309.
28. Dunlop, B.W., et al., *Predictors of remission in depression to individual and combined treatments (PreDICT): study protocol for a randomized controlled trial*. Trials, 2012. **13**: p. 106.
29. Shin, S.Y., et al., *An atlas of genetic influences on human blood metabolites*. Nat Genet, 2014. **46**(6): p. 543-550.
30. Lewinsohn, P.M., et al., *Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults*. Psychol Aging, 1997. **12**(2): p. 277-87.
31. Kroenke, K., R.L. Spitzer, and J.B. Williams, *The PHQ-9: validity of a brief depression severity measure*. J Gen Intern Med, 2001. **16**(9): p. 606-13.
32. Loewe, B., et al., *Gesundheitsfragebogen fuer Patienten (PHQ-D). Manual und Testunterlagen*. Second ed. 2002: Pfizer.
33. Rush, A.J., et al., *The Inventory of Depressive Symptomatology (IDS): psychometric properties*. Psychol Med, 1996. **26**(3): p. 477-86.
34. Smith, D.J., et al., *Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants*. PLoS One, 2013. **8**(11): p. e75362.

35. First, M.B., et al., *Structured Clinical Interview for the DSM-IV Axis Disorders (SCID PTSD Module)*, N.S.P.I. Biometrics Research Department, Editor. 1996: New York.
36. MahmoudianDehkordi, S., et al., *Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome*. *Alzheimers Dement*, 2019. **15**(1): p. 76-92.
37. McCarthy, S., et al., *A reference panel of 64,976 haplotypes for genotype imputation*. *Nat Genet*, 2016. **48**(10): p. 1279-83.
38. Willer, C.J., Y. Li, and G.R. Abecasis, *METAL: fast and efficient meta-analysis of genomewide association scans*. *Bioinformatics*, 2010. **26**(17): p. 2190-1.
39. Yavorska, O.O. and S. Burgess, *MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data*. *Int J Epidemiol*, 2017. **46**(6): p. 1734-1739.
40. Bakkaloglu, B., et al., *Platelet and Plasma Serotonin Levels and Platelet Monoamine Oxidase Activity in Patients with Major Depression: Effects of Sertraline Treatment*. *Turkish Journal of Biochemistry-Turk Biyokimya Dergisi*, 2008. **33**(3): p. 97-103.
41. Hess, S., et al., *Decreased serum L-arginine and L-citrulline levels in major depression*. *Psychopharmacology (Berl)*, 2017. **234**(21): p. 3241-3247.
42. Brunk, E., et al., *Recon3D enables a three-dimensional view of gene variation in human metabolism*. *Nat Biotechnol*, 2018. **36**(3): p. 272-281.
43. Lees, H.J., et al., *Hippurate: the natural history of a mammalian-microbial cometabolite*. *J Proteome Res*, 2013. **12**(4): p. 1527-46.
44. Bremner, J.D., K.D. Shearer, and P.J. McCaffery, *Retinoic acid and affective disorders: the evidence for an association*. *J Clin Psychiatry*, 2012. **73**(1): p. 37-50.
45. Landy, D., *Pibloktoq (hysteria) and Inuit nutrition: possible implication of hypervitaminosis A*. *Soc Sci Med*, 1985. **21**(2): p. 173-85.
46. O'Reilly, K., S.J. Bailey, and M.A. Lane, *Retinoid-mediated regulation of mood: possible cellular mechanisms*. *Exp Biol Med (Maywood)*, 2008. **233**(3): p. 251-8.
47. de Oliveira, M.R., et al., *The effects of vitamin A supplementation for 3 months on adult rat nigrostriatal axis: increased monoamine oxidase enzyme activity, mitochondrial redox dysfunction, increased β -amyloid(1-40) peptide and TNF- α contents, and susceptibility of mitochondria to an in vitro H2O2 challenge*. *Brain Res Bull*, 2012. **87**(4-5): p. 432-44.
48. Lane, M.A. and S.J. Bailey, *Role of retinoid signalling in the adult brain*. *Prog Neurobiol*, 2005. **75**(4): p. 275-93.
49. Mey, J. and P. McCaffery, *Retinoic acid signaling in the nervous system of adult vertebrates*. *Neuroscientist*, 2004. **10**(5): p. 409-21.
50. Bremner, J.D. and P. McCaffery, *The neurobiology of retinoic acid in affective disorders*. *Prog Neuropsychopharmacol Biol Psychiatry*, 2008. **32**(2): p. 315-31.
51. Gerber, L.E. and J.W. Erdman, Jr., *Changes in lipid metabolism during retinoid administration*. *J Am Acad Dermatol*, 1982. **6**(4 Pt 2 Suppl): p. 664-74.

52. Klör, H.U., et al., *The impact of oral vitamin A derivatives on lipid metabolism - What recommendations can be derived for dealing with this issue in the daily dermatological practice?* J Dtsch Dermatol Ges, 2011. **9**(8): p. 600-6.
53. Pallister, T., et al., *Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome.* Sci Rep, 2017. **7**(1): p. 13670.
54. Lassale, C., et al., *Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies.* Mol Psychiatry, 2019. **24**(7): p. 965-986.
55. Lončar, M., et al., *Coumarins in Food and Methods of Their Determination.* Foods, 2020. **9**(5).
56. Liu, B., et al., *A novel 4-hydroxycoumarin biosynthetic pathway.* Plant Mol Biol, 2010. **72**(1-2): p. 17-25.
57. Manolov, I., C. Maichle-Moessmer, and N. Danchev, *Synthesis, structure, toxicological and pharmacological investigations of 4-hydroxycoumarin derivatives.* Eur J Med Chem, 2006. **41**(7): p. 882-90.
58. von Känel, R., et al., *Depressive symptoms as a novel risk factor for recurrent venous thromboembolism: a longitudinal observational study in patients referred for thrombophilia investigation.* PLoS One, 2015. **10**(5): p. e0125858.
59. Kunutsor, S.K., S. Seidu, and K. Khunti, *Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence.* Ann Med, 2018. **50**(6): p. 529-537.
60. Lee, C.W., et al., *Depression and risk of venous thromboembolism: a population-based retrospective cohort study.* Psychosom Med, 2015. **77**(5): p. 591-8.
61. Sansone, R.A. and L.A. Sansone, *Warfarin and Antidepressants: Happiness without Hemorrhaging.* Psychiatry (Edgmont), 2009. **6**(7): p. 24-9.
62. Parkin, L., et al., *Antidepressants, Depression, and Venous Thromboembolism Risk: Large Prospective Study of UK Women.* J Am Heart Assoc, 2017. **6**(5).
63. Ferland, G., *Vitamin K and the nervous system: an overview of its actions.* Adv Nutr, 2012. **3**(2): p. 204-12.
64. Bartke, N. and Y.A. Hannun, *Bioactive sphingolipids: metabolism and function.* J Lipid Res, 2009. **50** Suppl(Suppl): p. S91-6.
65. Zeidan, Y.H. and Y.A. Hannun, *Translational aspects of sphingolipid metabolism.* Trends Mol Med, 2007. **13**(8): p. 327-36.
66. Cutler, R.G., et al., *Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.* Proc Natl Acad Sci U S A, 2004. **101**(7): p. 2070-5.
67. Jana, A., E.L. Hogan, and K. Pahan, *Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death.* J Neurol Sci, 2009. **278**(1-2): p. 5-15.
68. Posse de Chaves, E. and S. Sipione, *Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction.* FEBS Lett, 2010. **584**(9): p. 1748-59.

69. Gulbins, E., et al., *Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs*. Nat Med, 2013. **19**(7): p. 934-8.
70. Müller, C.P., et al., *Brain membrane lipids in major depression and anxiety disorders*. Biochim Biophys Acta, 2015. **1851**(8): p. 1052-65.
71. MacQueen, G.M., P.I. Rosebush, and M.F. Mazurek, *Neuropsychiatric aspects of the adult variant of Tay-Sachs disease*. J Neuropsychiatry Clin Neurosci, 1998. **10**(1): p. 10-9.
72. Cole, A.L., et al., *Depression in adults with Fabry disease: a common and under-diagnosed problem*. J Inherit Metab Dis, 2007. **30**(6): p. 943-51.
73. Laney, D.A., et al., *Social-adaptive and psychological functioning of patients affected by Fabry disease*. J Inherit Metab Dis, 2010. **33 Suppl 3**: p. S73-81.
74. Sadek, J., et al., *Psychiatric findings in four female carriers of Fabry disease*. Psychiatr Genet, 2004. **14**(4): p. 199-201.
75. Packman, W., et al., *Psychological complications of patients with Gaucher disease*. J Inherit Metab Dis, 2006. **29**(1): p. 99-105.
76. MahmoudianDehkordi, S., et al., *Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression*. Transl Psychiatry, 2021. **11**(1): p. 153.
77. Awuchi, C., *Sugar Alcohols: Chemistry, Production, Health Concerns and Nutritional Importance of Mannitol, Sorbitol, Xylitol, and Erythritol*. International Journal of Advanced Academic Research, 2017. **3**: p. 2488-9849.
78. Ledochowski, M., et al., *Fructose- and sorbitol-reduced diet improves mood and gastrointestinal disturbances in fructose malabsorbers*. Scand J Gastroenterol, 2000. **35**(10): p. 1048-52.
79. Janowsky, D.S., M.K. el-Yousef, and J.M. Davis, *Acetylcholine and depression*. Psychosom Med, 1974. **36**(3): p. 248-57.
80. Hirsch, M.J. and R.J. Wurtman, *Lecithin consumption increases acetylcholine concentrations in rat brain and adrenal gland*. Science, 1978. **202**(4364): p. 223-5.
81. Magil, S.G., S.H. Zeisel, and R.J. Wurtman, *Effects of ingesting soy or egg lecithins on serum choline, brain choline and brain acetylcholine*. J Nutr, 1981. **111**(1): p. 166-70.
82. Löffelholz, K., J. Klein, and A. Köppen, *Choline, a precursor of acetylcholine and phospholipids in the brain*. Prog Brain Res, 1993. **98**: p. 197-200.
83. Puri, P., et al., *A lipidomic analysis of nonalcoholic fatty liver disease*. Hepatology, 2007. **46**(4): p. 1081-90.
84. Callaerts-Vegh, Z., et al., *LPA5 receptor plays a role in pain sensitivity, emotional exploration and reversal learning*. Genes Brain Behav, 2012. **11**(8): p. 1009-19.
85. Moreno-Fernández, R.D., et al., *maLPA1-null mice as an endophenotype of anxious depression*. Transl Psychiatry, 2017. **7**(4): p. e1077.
86. Saldanha, D., et al., *Serum Serotonin Abnormality in Depression*. Med J Armed Forces India, 2009. **65**(2): p. 108-12.
87. Wood, K., J. Harwood, and A. Coppen, *The effect of antidepressant drugs on plasma kynurenine in depressed patients*. Psychopharmacology (Berl), 1978. **59**(3): p. 263-6.

88. Alvarez, J.C., et al., *Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response?* Psychopharmacology (Berl), 1999. **143**(1): p. 97-101.
89. Inoshita, M., et al., *Elevated peripheral blood glutamate levels in major depressive disorder.* Neuropsychiatr Dis Treat, 2018. **14**: p. 945-953.
90. Ogawa, S., et al., *Plasma amino acid profile in major depressive disorder: Analyses in two independent case-control sample sets.* J Psychiatr Res, 2018. **96**: p. 23-32.
91. Ali-Sisto, T., et al., *Global arginine bioavailability ratio is decreased in patients with major depressive disorder.* J Affect Disord, 2018. **229**: p. 145-151.
92. Rotroff, D.M., et al., *Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.* Transl Psychiatry, 2016. **6**(9): p. e894.
93. Guerreiro, J.R., et al., *Argininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide: role in arginine and nitric oxide production.* J Biol Chem, 2009. **284**(30): p. 20022-33.
94. Bahri, S., et al., *Citrulline: from metabolism to therapeutic use.* Nutrition, 2013. **29**(3): p. 479-84.
95. Fewell, Z., G. Davey Smith, and J.A. Sterne, *The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study.* Am J Epidemiol, 2007. **166**(6): p. 646-55.

SUPPLEMENTARY MATERIAL

Full version of supplementary materials can be found through the following link:

<https://assets.researchsquare.com/files/rs-1815755/v1/b5558213de1f6214d9a49648.docx>

<https://assets.researchsquare.com/files/rs-1815755/v1/69dea74aa784af1fbd638dbb.docx>

<https://assets.researchsquare.com/files/rs-1815755/v1/8614958ffbce5f372aba9ce7.pdf>